Clinical

Dataset Information

0

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer


ABSTRACT: The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).

DISEASE(S): Solid Tumor,Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2229069 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2134496 | ecrin-mdr-crc
| 2302806 | ecrin-mdr-crc
| 2111195 | ecrin-mdr-crc
2015-12-25 | GSE75435 | GEO
2012-10-19 | E-MTAB-923 | biostudies-arrayexpress
| 2109274 | ecrin-mdr-crc
| 2067755 | ecrin-mdr-crc
| 2129434 | ecrin-mdr-crc
| 2219712 | ecrin-mdr-crc
| 2091322 | ecrin-mdr-crc